Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789019 | 0.88 | SMN1; SMN2 (0.41) | MAPTUBE2NL3MBTL1APAF1MAPK1 | |
| SCHEMBL4786438 | 0.87 | CNR1 (0.43) | CNR1CNR2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL4897158 | 0.84 | MAPT (0.41) | MAPTKDM4EALDH1A1HPGD | |
| SCHEMBL4894672 | 0.83 | MAPK14 (0.34) | CNR1CNR2MAPTL3MBTL1MAPK1 | |
| SCHEMBL4897672 | 0.82 | FFAR2 (0.40) | MAPTL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4899257 | 0.81 | GRN (0.42) | MAPTL3MBTL1MAPK1CASP3SENP8 | |
| SCHEMBL3290393 | 0.80 | LMNA (0.41) | MAPTSMN1; SMN2ALDH1A1ADORA1KMT2A | |
| SCHEMBL14020621 | 0.79 | KDM4E (0.34) | MAPTSMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL4897212 | 0.78 | KDM4E (0.42) | MAPTMAPK1KDM4ENPC1RAB9A | |
| SCHEMBL14045306 | 0.76 | LMNA (0.37) | CNR2MAPTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | claimed |
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | GABRB2, GABRA2, GABBR2 | CNR1 82/4885CNR2 54/4885MAPT 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.